logo


FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Expires:February 28, 2011
Estimated average burden
hours per response0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LEE KENNETH B JR

(Last)(First)(Middle)
C/O OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD

(Street)
MELVILLENY11747

(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
OSI PHARMACEUTICALS INC [OSIP]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2009
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock 06/17/2009 A  1,500 (1) A$ 0 11,500 D  

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $ 28.65 06/17/2009 A  3,000  06/17/2010(2)06/16/2016 Common Stock 3,000 $ 0 3,000 (3) D  
Explanation of Responses:
1. Represents the formula grant of Deferred Stock Units to the director upon his re-election to the Board of Directors of OSI Pharmaceuticals, Inc. 25% of the Deferred Stock Units vest one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. Mr. Lee will receive one share of OSI stock for each vested Deferred Stock Unit that he holds upon the termination of his service on OSI Pharmaceuticals, Inc.'s Board of Directors.
2. 25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years.
3. Includes only options with the same termination date.
 
Remarks:
Exhibit List
Exhibit 24--Power of Attorney
/s/ Pierre Legault, attorney-in-fact for Mr. Lee06/19/2009
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
Know all by these presents that the undersigned hereby
constitutes and appoints Pierre Legault with full power of
substitution and re-substitution, the undersigned's  true and lawful
attorney-in-fact to:
(1)execute for and on behalf of the undersigned,
in the undersigned's capacity as an officer and/or director of
OSI Pharmaceuticals, Inc. (the "Company") Forms 3, 4, and 5 in
accordance with Section 16(a) of the Securities
Act of 1934, and the rules thereunder:
(2)do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable
to complete and execute  any such Form 3,
Form 4 or Form 5, complete and execute any
amendment or amendments thereto,  and timely file such
form with the United States Securities and
Exchange Commission and any stock exchange or
similar authority; and
(3)take any other action of any type whatsoever in
connection with the foregoing which in the
opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally
required by, the undersigned, it being
understood that the documents executed by such
attorney in fact on behalf of the undersigned
pursuant to this Power of  Attorney shall be in
such form and shall contain such terms and
conditions as such attorney-in-fact may approve
in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-
in-fact full power and authority to do and perform any
and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any
of the rights and powers herein granted, as fully to
all intents and purposes as the undersigned might or
could do if personally present, with full power of
substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such
attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this
power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to
file Forms 3, 4 and 5 with respect to the undersigned's
holdings of, and transactions in securities issued by
the Company unless earlier revoked by the
undersigned in a signed writing delivered to
the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has executed
 this Power of Attorney as of this 24th day of December, 2008.
By:  /s/ Kenneth B. Lee, Jr.

Add to Delicious   Add to DeliciousDigg It  Digg It
Send Email Send by Email Send Email Post Comment

 
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia